Skip to main content

What the FDA labels say about taking them together

Erlotinib and teriflunomide

Erlotinib's FDA label of June 10, 2024 names teriflunomide in its drug interactions section; the teriflunomide label PlainMeds reads does not name erlotinib. The erlotinib label: “Avoid smoking tobacco (CYP1A2 inducer) and avoid concomitant use of erlotinib with moderate CYP1A2 inducers.”

Check it at the source: the erlotinib FDA label on DailyMed (effective June 10, 2024, Alembic Pharmaceuticals Limited); the teriflunomide FDA label on DailyMed (effective February 20, 2026, Genzyme Corporation).

What does the erlotinib label say about teriflunomide?

Erlotinib label, drug interactions

Avoid smoking tobacco (CYP1A2 inducer) and avoid concomitant use of erlotinib with moderate CYP1A2 inducers (e.g., teriflunomide, rifampin, or phenytoin).

Source: FDA drug label (ERLOTINIB HYDROCHLORIDE), Alembic Pharmaceuticals Limited, effective June 10, 2024 (SPL set ab6f3cb3-34a8-4492-a5d7-fb6b055a2d6b), via openFDA; the full label on DailyMed

What does the teriflunomide label say about erlotinib?

Teriflunomide's label (effective February 20, 2026) does not name erlotinib in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Aubagio), NDA202992 (Sanofi Aventis Us), as published by Genzyme Corporation, effective February 20, 2026 (SPL set 4650d12c-b9c8-4525-b07f-a2d773eca155), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

10Erlotinib generic labelers
15Teriflunomide generic labelers
ErlotinibTeriflunomide
Labeled forLung cancerMultiple sclerosis
Boxed warningNoYes
Pharmacy cost (NADAC)n/a$0.233 per tablet 14 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?